Outcomes of Autologous Stem Cell Transplant in Patients with Ultra High-Risk Multiple Myeloma.
Transplantation and cellular therapy（2023）
摘要
MM patients with ultra high-risk MM have a median PFS of <24 months with the current standard of care that includes consolidation with autoHCT. These patients may benefit from earlier use of newer treatment modalities, such as CAR-T and bispecific antibodies.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要